A detailed history of Rice Hall James & Associates, LLC transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 223,589 shares of OCUP stock, worth $288,429. This represents 0.02% of its overall portfolio holdings.

Number of Shares
223,589
Previous 291,985 23.42%
Holding current value
$288,429
Previous $586,000 41.64%
% of portfolio
0.02%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$1.51 - $2.23 $103,277 - $152,523
-68,396 Reduced 23.42%
223,589 $342,000
Q1 2024

Apr 23, 2024

SELL
$1.89 - $3.27 $528,806 - $914,919
-279,792 Reduced 48.93%
291,985 $586,000
Q4 2023

Feb 08, 2024

SELL
$2.59 - $3.64 $665,244 - $934,937
-256,851 Reduced 31.0%
571,777 $1.72 Million
Q3 2023

Nov 02, 2023

SELL
$3.35 - $4.33 $69,204 - $89,449
-20,658 Reduced 2.43%
828,628 $2.78 Million
Q2 2023

Jul 24, 2023

BUY
$3.63 - $6.38 $145,813 - $256,278
40,169 Added 4.96%
849,286 $3.69 Million
Q1 2023

May 11, 2023

BUY
$3.01 - $3.85 $9,180 - $11,742
3,050 Added 0.38%
809,117 $3.03 Million
Q4 2022

Jan 27, 2023

BUY
$2.04 - $3.53 $542,066 - $937,988
265,719 Added 49.18%
806,067 $0
Q3 2022

Nov 01, 2022

BUY
$1.82 - $2.79 $387,394 - $593,862
212,854 Added 64.99%
540,348 $1.09 Million
Q2 2022

Aug 08, 2022

BUY
$1.8 - $3.25 $328,442 - $593,021
182,468 Added 125.82%
327,494 $629,000
Q1 2022

May 05, 2022

BUY
$2.75 - $4.39 $34,630 - $55,283
12,593 Added 9.51%
145,026 $470,000
Q4 2021

Feb 14, 2022

BUY
$3.4 - $5.19 $450,272 - $687,327
132,433 New
132,433 $494,000

Others Institutions Holding OCUP

About Ocuphire Pharma, Inc.


  • Ticker OCUP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,579,800
  • Market Cap $26.5M
  • Description
  • Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...
More about OCUP
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.